Astion Pharma (Three Products Worldwide Rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Astion Pharma (Three Products Worldwide Rights) General Information

Description

Portfolio of manufacturing rights for three dermatological drugs. The portfolio encompasses worldwide rights for Dermadexin, a topical treatment for seborrheic dermatitis; Pruridexin, a topical cream to treat chronic puritis; and ASF-1096, a treatment for discoid lupus erythematosus.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Corporate Office
  • Denmark

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Astion Pharma (Three Products Worldwide Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Astion Pharma (Three Products Worldwide Rights)‘s full profile, request access.

Request a free trial

Astion Pharma (Three Products Worldwide Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Astion Pharma (Three Products Worldwide Rights)‘s full profile, request access.

Request a free trial

Astion Pharma (Three Products Worldwide Rights) FAQs

  • Where is Astion Pharma (Three Products Worldwide Rights) headquartered?

    Astion Pharma (Three Products Worldwide Rights) is headquartered in Denmark.

  • What industry is Astion Pharma (Three Products Worldwide Rights) in?

    Astion Pharma (Three Products Worldwide Rights)’s primary industry is Buildings and Property.

  • Is Astion Pharma (Three Products Worldwide Rights) a private or public company?

    Astion Pharma (Three Products Worldwide Rights) is a Private company.

  • What is the current valuation of Astion Pharma (Three Products Worldwide Rights)?

    The current valuation of Astion Pharma (Three Products Worldwide Rights) is 00.000.

  • What is Astion Pharma (Three Products Worldwide Rights)’s current revenue?

    The current revenue for Astion Pharma (Three Products Worldwide Rights) is 000000.

  • Who are Astion Pharma (Three Products Worldwide Rights)’s investors?

    Astion Pharma has invested in Astion Pharma (Three Products Worldwide Rights).

  • When was Astion Pharma (Three Products Worldwide Rights) acquired?

    Astion Pharma (Three Products Worldwide Rights) was acquired on 26-Feb-2015.

  • Who acquired Astion Pharma (Three Products Worldwide Rights)?

    Astion Pharma (Three Products Worldwide Rights) was acquired by Cipher Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »